Better Buy: Novavax vs. Roche
Boxers of different weight classes aren't supposed to fight against each other. Lightweights shouldn't be in the ring with heavyweights. If stocks were boxers, Novavax (NASDAQ: NVAX) would probably be a lightweight with its market cap of around $8 billion. Roche Holdings (OTC: RHHBY) would definitely be a heavyweight with its market cap above $300 billion.
But investing isn't like boxing. Every stock, regardless of size, competes against one another to win your investing dollars. And sometimes lightweights pummel heavyweights. So far this year, for example, Novavax stock has skyrocketed over 3,400% while Roche is up nearly 12%. Which of these stocks is more likely to be the champion over the long run?
Image source: Getty Images.
Source Fool.com
